Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Conditions: Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis Interventions: Drug: Bedaquiline Oral Tablet; Drug: Linezolid Oral Tablet; Drug: Delamanid in Oral Dosage Form; Drug: Clofazimine Oral Product; Drug: Levofloxacin Oral Tablet; Drug: Isoniazid Oral Product; Drug: Ethambutol Oral Product; Drug: Pyrazinamide Oral Pro duct Sponsors: Wits Health Consortium (Pty) Ltd; Regents of the University of California; University of Cape Town; Perinatal HIV Research Unit of the University of the Witswatersrand Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Bedaquiline | Linezolid | Perinatology & Neonatology | Research | South Africa Health | Tuberculosis | Zyvox